logo-loader

M Pharmaceutical rebrands to highlight its family of biomedical technologies

Last updated: 12:45 16 Jul 2015 EDT, First published: 10:45 16 Jul 2015 EDT

pharma_manufacturing_350_55a7cd9db6b13
M Pharma’s new corporate identity highlights its efforts to develop and sell innovative biomedical technologies based on the principle

M Pharmaceutical (CSE:MQ) (OTCQB:MPHMF) unveiled the core of its new corporate and product identity under the mantra "Better Health. Better Life".

The corporate rebranding aims to better promote its emerging family of biomedical technologies, which include the eMosquito Wearable Blood Monitor, now joined by the Trimeo Weight Loss Capsules and the Trimtec Gastric Stimulation System.

"Our new approach and communications platform will help us in our pursuit of excellence in the biomedical technologies that we believe will make a palpable difference in the lives of people living with obesity and diabetes. The rebranding simplifies the comprehensive vision of M Pharmaceutical, Inc. and crystalizes the story behind the eMosquito. In introducing Trimeo and Trimtec to our family, it represents an exciting new chapter in the growth and development of our company," said M Pharma’s president and CEO, Dr. Martin Mintchev.           

M Pharma’s new corporate identity highlights its efforts to develop and sell innovative biomedical technologies based on the principle of reducing invasiveness while still affording end users realistic solutions and enhanced effectiveness. 

The corporate brand mark and all product marks will share the common ‘M’ in a colour-coded protocol to be consistently applied across all communications platforms while its family of biomedical products will be linked by the "M" embedded in a stylized Circle of Life, said the company in a statement:

"The Circle of Life that will represent M Pharmaceutical, Inc. going forward is designed to remind all of us and our stakeholders of the importance of collaboration in the execution of our business plan and invoke the targeted focus we have around providing integrated solutions for the people who need our biomedical technologies most," added Dr. Mintchev.              

M Pharma decided to rebrand in order to assemble its biomedical technology products under one roof:

"Based on the quality of people who have joined with Dr. Mintchev on our leadership team, our Board and our Advisory group, and given the progress the team has made on all fronts, we believed it was the right time to usher in our new look and feel," said M Pharmaceutical board of directors member, George Tsafalas.             

Meanwhile, in late June, SeeThruEquity, an independent small cap and microcap focused equity research firm started covering M Pharmaceutical with a price target of US$0.65/CAD$0.79 per share, implying an upside of 315.8% from a June high of $0.19.

Vancouver based M Pharma is pursuing an ambitious brand development strategy as it builds on a successful round of biotech acquisitions focused on the treatment of diabetes and obesity.

Over the past three months, M Pharmaceutical Inc. has acquired three biomedical technologies addressing obesity and diabetes in a less invasive manner than its market competitors. This process started with M Diagnostics, as announced last February 19, which held the right to eMosquito.

The emosquito Wearable Blood Monitor, deploys mosquito technology for automatic and autonomous monitoring of blood glucose by diabetics.

The other key technologies, Trimeo Weight Loss Capsules, a drug free, individually controllable solution that induces a feeling of early satiety and the TrimTec Gastric Stimulation System, an innovative and minimally invasive surgical solution for significant weight loss.

The analyst suggests M Pharma can draw tremendous potential when it gets regulatory clearance for its promising family of biomedical technologies addressing the multi-billion dollar obesity and diabetes sector. This market should grow 6.9% per year, rising from C$148.1 billion in 2014 to an estimated C$206.4 billion in 2019.

M Pharma first listed on the market after merging with First Sahara Energy, Inc. in February 2015. Over the past few weeks, M Pharma completed a 10:1 share consolidation to bring shares outstanding more in line with peers.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 15 minutes ago